Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 201–300 of 1,008
Peters, S., Felip, E., Dafni, U., Belka, C., Guckenberger, M., Irigoyen, A., Nadal, E., Becker, A., Vees, H., Pless, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.001 · Cited by 162
The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
Boustani, J., Grapin, M., Laurent, P.-A., Apétoh, L., & Mirjolet, C. (2019) · Cancers · doi:10.3390/cancers11060860 · Cited by 199
Current status and perspectives of esophageal cancer: a comprehensive review
Jiang, W., Zhang, B., Xu, J., Xue, L., & Wang, L. (2024) · 癌症:英文版 · doi:10.1002/cac2.12645 · Cited by 223
Su, Q., Zhu, E. C., Wu, J.-B., Li, T., Hou, Y.-L., Wang, D.-Y., & Gao, Z.-H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00108 · Cited by 161
Im, J. H., Buzzelli, J. N., Jones, K., Franchini, F., Gordon-Weeks, A., Markelc, B., Chen, J., Kim, J., Cao, Y., & Muschel, R. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17914-x · Cited by 161
Salas Fragomeni, R. A., Amir, T., Sheikhbahaei, S., Harvey, S. C., Javadi, M. S., Solnes, L. B., Kiess, A. P., Allaf, M. E., Pomper, M. G., Gorin, M. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203570 · Cited by 156
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Sivanandam, V., LaRocca, C. J., Chen, N. G., Fong, Y., & Warner, S. G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.04.003 · Cited by 176
Management of locally advanced non‐small cell lung cancer: State of the art and future directions
Miao, D., Zhao, J., Han, Y., Zhou, J., Li, X., Zhang, T., Li, W., & Xia, Y. (2023) · 癌症:英文版 · doi:10.1002/cac2.12505 · Cited by 188
Integration of radiotherapy and immunotherapy for treatment of oligometastases
Pitroda, S. P., Chmura, S. J., & Weichselbaum, R. R. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30157-3 · Cited by 167
Update on Immunohistochemistry for the Diagnosis of Lung Cancer
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10030072 · Cited by 183
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
Menon, H., Ramapriyan, R., Cushman, T. R., Verma, V., Kim, H. H., Schoenhals, J. E., Atalar, S. C., Selek, U., Chun, S. G., Chang, J. Y., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00193 · Cited by 171
Schuemann, J., Bagley, A. F., Berbeco, R., Bromma, K., Butterworth, K. T., Byrne, H. L., Chithrani, B. D., Cho, S. H., Cook, J. R., Favaudon, V., et al. (2020) · Physics in Medicine & Biology · doi:10.1088/1361-6560/ab9159 · Cited by 155
PD-L1 expression testing in non-small cell lung cancer
Teixidó, C., Vilariño, N., Reyes, R., & Reguart, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918763493 · Cited by 156
Ji, D., Song, C., Li, Y., Xia, J., Wu, Y., Jia, J., Cui, X., Yu, S., & Gu, J. F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000826 · Cited by 166
Radiotherapy and immunotherapy: open questions and future strategies
Pointer, K. B., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.003 · Cited by 173
Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer
Cho, Y., Park, S. J., Byun, H. K., Lee, C. G., Cho, J., Hong, M. H., Kim, H. R., Cho, B. C., Kim, S., Park, J., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.08.047 · Cited by 165
Self-citationSynthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 167
Planchard, D., Reinmuth, N., Orlov, S., Fischer, J. R., Sugawara, S., Mandziuk, S., Marquez-Medina, D., Novello, S., Takeda, Y., Soo, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.006 · Cited by 153
Self-citationImmunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 175
Diggs, L. P., Ruf, B., Ma, C., Heinrich, B., Cui, L., Zhang, Q., McVey, J. C., Wabitsch, S., Heinrich, S., Rosato, U., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.037 · Cited by 151
Radiation Pneumonitis: Old Problem, New Tricks
Jain, V., & Berman, A. T. (2018) · Cancers · doi:10.3390/cancers10070222 · Cited by 167
Video‐assisted thoracoscopic surgery as the gold standard for lung cancer surgery
Sihoe, A. D. L. (2020) · Respirology · doi:10.1111/resp.13920 · Cited by 180
Sun, X., Roudi, R., Dai, T., Chen, S., Fan, B., Li, H., Zhou, Y., Zhou, M., Zhu, B., Yin, C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5701-6 · Cited by 160
Ricciuti, B., Recondo, G., Spurr, L. F., Li, Y. Y., Lamberti, G., Venkatraman, D., Umeton, R., Cherniack, A. D., Nishino, M., Sholl, L. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3529 · Cited by 151
Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 193
Janjigian, Y. Y., Cutsem, E. V., Muro, K., Wainberg, Z. A., Al‐Batran, S., Hyung, W. J., Molena, D., Marcovitz, M., Ruscica, D., Robbins, S. H., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0093 · Cited by 163
Combining chemotherapy with PD-1 blockade in NSCLC
Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.003 · Cited by 145
Owen, D. H., Wei, L., Bertino, E. M., Edd, T., Villalona-Calero, M. A., He, K., Shields, P. G., Carbone, D. P., & Otterson, G. A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.008 · Cited by 145
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N., & Neilan, T. G. (2021) · JACC: CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 141
The Promise of Combining Radiation Therapy With Immunotherapy
Jagodinsky, J. C., Harari, P. M., & Morris, Z. S. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.04.023 · Cited by 154
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials
Monk, B. J., Enomoto, T., Kast, W. M., McCormack, M. M., Tan, D. S. P., Wu, X., & González-Martín, A. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102385 · Cited by 152
Kordbacheh, T., Honeychurch, J., Blackhall, F. H., Finn, C. F., & Illidge, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx790 · Cited by 152
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
van Willigen, W. W., Bloemendal, M., Gerritsen, W. R., Schreibelt, G., de Vries, I. J. M., & Bol, K. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02265 · Cited by 150
Sears, C. R., Peikert, T., Possick, J. D., Naidoo, J., Nishino, M., Patel, S. P., Camus, P., Gaga, M., Garon, E. B., Gould, M. K., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201906-1202st · Cited by 141
An update on the immune landscape in lung and head and neck cancers
Carlisle, J. W., Steuer, C. E., Owonikoko, T. K., & Saba, N. F. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21630 · Cited by 161
Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X., & Zhang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01430 · Cited by 153
Checkpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Tsang, V. H. M., McGrath, R. T., Clifton-Bligh, R. J., Scolyer, R. A., Jakrot, V., Guminski, A. D., Long, G. V., & Menzies, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00423 · Cited by 139
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC
Lin, S. H., Lin, Y. H., Yao, L., Kalhor, N., Carter, B. W., Altan, M., Blumenschein, G. R., Byers, L. A., Fossella, F. V., Gibbons, D. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.024 · Cited by 150
Heymach, J. V., Krilov, L., Alberg, A. J., Baxter, N. N., Chang, S. M., Corcoran, R. B., Dale, W., DeMichele, A. M., Diefenbach, C., Dreicer, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0446 · Cited by 167
Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors
Bott, M. J., Cools‐Lartigue, J., Tan, K. S., Dycoco, J., Bains, M. S., Downey, R. J., Huang, J. G., Isbell, J. M., Molena, D., Park, B. J., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.02.030 · Cited by 141
Garassino, M. C., Mazières, J., Reck, M., CHOUAID, C., Bischoff, H. G., Reinmuth, N., Cove-Smith, L., Mansy, T., Cortinovis, D. L., Migliorino, M. R., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.07.1148 · Cited by 152
Self-citationClinical assessment of immune-related adverse events
Sosa, A., Lopez Cadena, E., Simon Olive, C., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 132
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 146
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Kooshkaki, O., Derakhshani, A., Hosseinkhani, N., Torabi, M., Safaei, S., Brunetti, O., Racanelli, V., Silvestris, N., & Baradaran, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124427 · Cited by 147
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Wirsdörfer, F., de Leve, S., & Jendrossek, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010024 · Cited by 139
Recent advances of PET imaging in clinical radiation oncology
Unterrainer, M., Eze, C., Ilhan, H., Marschner, S. N., Roengvoraphoj, O., Schmidt-Hegemann, N.-S., Walter, F., Kunz, W. G., af Rosenschöld, P. M., Jeraj, R., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01519-1 · Cited by 159
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Aredo, J. V., Mambetsariev, I., Hellyer, J. A., Amini, A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Naidoo, J., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1628 · Cited by 137
Wang, L., Lynch, C. M., Pitroda, S. P., Piffkó, A., Yang, K., Huser, A. K., Liang, H. L., & Weichselbaum, R. R. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232101 · Cited by 155
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Shen, X., Zhang, L., Li, J., Li, Y., Wang, Y., & Xu, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01337 · Cited by 139
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Yang, T., Kong, Z., & Ma, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1782692 · Cited by 152
Bendell, J. C., LoRusso, P. M., Overman, M. J., Noonan, A. M., Kim, D., Strickler, J. H., Kim, S., Clarke, S. J., George, T. J., Grimison, P., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03430-6 · Cited by 147
Darragh, L. B., Oweida, A. J., & Karam, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03154 · Cited by 140
Biomarkers of Radiotherapy-Induced Immunogenic Cell Death
Vaes, R. D. W., Hendriks, L. E. L., Vooijs, M., & Ruysscher, D. D. (2021) · Cells · doi:10.3390/cells10040930 · Cited by 141
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 145
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Catanzaro, E., Beltrán‐Visiedo, M., Galluzzi, L., & Krysko, D. V. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01245-8 · Cited by 150
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Tang, Z.-H., & Lu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.004 · Cited by 132
Tio, M., Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Khoo, C., Park, J. J., Spain, L., Turajlic, S., Ardolino, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.017 · Cited by 129
Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment
Zhu, S., Wang, Y., Tang, J., & Cao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074477 · Cited by 155
Role of immune-checkpoint inhibitors in lung cancer
Jain, P., Jain, C., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750075 · Cited by 139
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 142
Quan, Z., Yang, Y., Zheng, H., Zhan, Y., Luo, J., Ning, Y., & Fan, S. (2022) · Journal of Cancer · doi:10.7150/jca.77619 · Cited by 143
The clinical utility of tumor mutational burden in non-small cell lung cancer
Greillier, L., Tomasini, P., & Barlési, F. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.08 · Cited by 131
Yoneda, K., Kuwata, T., Kanayama, M., Mori, M., Kawanami, T., Yatera, K., Ohguri, T., Hisaoka, M., Nakayama, T., & Tanaka, F. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0541-3 · Cited by 130
Ghini, V., Laera, L., Fantechi, B., Monte, F. D., Benelli, M., McCartney, A., Tenori, L., Luchinat, C., & Pozzessere, D. (2020) · Cancers · doi:10.3390/cancers12123574 · Cited by 140
Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review
Yan, Y., Fu, J., Kowalchuk, R. O., Wright, C. M., Zhang, R., Li, X., & Xu, Y. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-108 · Cited by 135
Naidoo, J., Antonia, S. J., Wu, Y.-L. L. C., Cho, B. C., Thiyagarajah, P., Mann, H., Newton, M., & Finn, C. F. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.02.009 · Cited by 135
Self-citationRuysscher, D. D., Dingemans, A. C., Praag, J. O., Belderbos, J. S. A., Tissing-Tan, C. J. A., Herder, J., Haitjema, T. J., Ubbels, F. J. F., Lagerwaard, F. J., Sharouni, S. Y. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.5817 · Cited by 122
Immune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 150
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Cai, X., Jin, J., Zhang, M., Liu, A. Y., Wang, J., Mohan, R., Kong, F., & Lin, S. H. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.02.015 · Cited by 136
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 121
Immune Checkpoint Inhibition in Head and Neck Cancer
Forster, M. D., & Devlin, M.-J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00310 · Cited by 135
Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer
Eckert, F., Schilbach, K., Klumpp, L., Bardoscia, L., Sezgın, E., Schwab, M. G., Zips, D., & Huber, S. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03018 · Cited by 130
Shoji, F., Takeoka, H., Kozuma, Y., Toyokawa, G., Yamazaki, K., Ichiki, M., & Takeo, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.006 · Cited by 138
Immune checkpoint inhibitors in advanced non–small cell lung cancer
Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2018) · Cancer · doi:10.1002/cncr.31105 · Cited by 121
Heymach, J. V., Mitsudomi, T., Harpole, D. H., Aperghis, M., Jones, S., Mann, H., Fouad, T. M., & Reck, M. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.09.010 · Cited by 136
Noninvasive PET Imaging of T cells
Wei, W., Jiang, D., Ehlerding, E. B., Luo, Q., & Cai, W. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.009 · Cited by 125
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 114
Zhang, W., Yan, C., Gao, X., Li, X., Cao, F., Zhao, G., Zhao, J., Er, P., Zhang, T., Chen, X., et al. (2021) · The Oncologist · doi:10.1002/onco.13797 · Cited by 127
Zhang, Q., Tang, L., Zhou, Y., He, W., & Li, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663986 · Cited by 136
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 129
Future of Radiotherapy in Nasopharyngeal Carcinoma
Sun, X.-S., Li, X. N., Chen, Q.-Y., Tang, L., & Mai, H. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190209 · Cited by 124
Pinzani, P., D’Argenio, V., Re, M. D., Pellegrini, C., Cucchiara, F., Salvianti, F., & Galbiati, S. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1685 · Cited by 135
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 134
Lazzari, C., Karachaliou, N., Bulotta, A., Viganó, M., Mirabile, A., Brioschi, E., Santarpia, M., Gianni, L., Rosell, R., & Gregorc, V. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918762094 · Cited by 117
Voong, K. R., Hazell, S. Z., Fu, W., Hu, C., Lin, C. T., Ding, K., Suresh, K. S., Hayman, J., Hales, R. K., Alfaifi, S. A., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.018 · Cited by 127
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 122
Li, M., Spakowicz, D. J., Burkart, J. T., Patel, S. P., Husain, M., He, K., Bertino, E. M., Shields, P. G., Carbone, D. P., Verschraegen, C. F., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02982-4 · Cited by 129
Lambin, P., Lieverse, R. I. Y., Eckert, F., Marcus, D., Oberije, C., van der Wiel, A. M.-M. A., Guha, C., Dubois, L. J., & Deasy, J. O. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.003 · Cited by 136
Geng, Y., Zhang, Q., Feng, S., Li, C., Wang, L., Zhao, X., Yang, Z., Li, Z., Luo, H., Liu, R., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3718 · Cited by 129
Powell, S. F., Gold, K. A., Gitau, M. M., Sumey, C. J., Lohr, M. M., McGraw, S. C., Nowak, R. K., Jensen, A. W., Blanchard, M. J., Fischer, C. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03156 · Cited by 116
Hubbeling, H., Lebow, E. S., Horick, N., Goodwin, K. E., Lin, J. J., Oh, K. S., Shaw, A. T., Mehan, W. A., Shih, H. A., & Gainor, J. F. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.012 · Cited by 120
Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer
Muchnik, E., Loh, K. P., Strawderman, M. S., Magnuson, A. M., Mohile, S. G., Estrah, V., & Maggiore, R. J. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15750 · Cited by 122
Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases
Dağoğlu, N., Karaman, Ş., Çağlar, H. B., & Oral, E. N. (2019) · Cureus · doi:10.7759/cureus.4103 · Cited by 130
Combinatorial therapy in tumor microenvironment: Where do we stand?
Kumari, S., Advani, D., Sharma, S., Ambasta, R. K., & Kumar, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188585 · Cited by 130
Lopci, E., Hicks, R. J., Dimitrakopoulou‐Strauss, A., Dercle, L., Iravani, A., Seban, R., Sachpekidis, C., Humbert, O., Gheysens, O. S., Glaudemans, A. W. J. M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05780-2 · Cited by 128
The current treatment landscape in the UK for stage III NSCLC
Limited, O. B. O. A. U., & Evison, M. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01069-z · Cited by 125
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.